Cannell & Spears LLC Has $7.84 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Cannell & Spears LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 107.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,888 shares of the medical research company's stock after purchasing an additional 20,678 shares during the period. Cannell & Spears LLC's holdings in IQVIA were worth $7,838,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in IQV. Smith Group Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter worth about $1,616,000. Nordea Investment Management AB boosted its position in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after buying an additional 452,029 shares during the period. Hickory Asset Management Inc. bought a new position in IQVIA in the 4th quarter worth approximately $941,000. Fifth Third Bancorp raised its stake in IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock valued at $2,590,000 after acquiring an additional 1,521 shares in the last quarter. Finally, Graphene Investments SAS boosted its position in IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock worth $2,948,000 after acquiring an additional 2,700 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IQV. UBS Group cut their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Truist Financial reiterated a "buy" rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. JPMorgan Chase & Co. cut their target price on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Finally, Barclays decreased their target price on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and a consensus price target of $249.05.

IQVIA Stock Down 5.1 %

Shares of IQV stock traded down $8.56 during trading on Friday, hitting $159.13. 887,352 shares of the company were exchanged, compared to its average volume of 1,480,865. The business's 50-day simple moving average is $190.67 and its 200 day simple moving average is $204.66. IQVIA Holdings Inc. has a twelve month low of $155.65 and a twelve month high of $252.88. The firm has a market capitalization of $28.06 billion, a price-to-earnings ratio of 21.20, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.